`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`LUPIN LTD. and LUPIN PHARMACEUTICALS INC.
`Petitioners
`
`v.
`
`SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and
`BAUSCH & LOMB PHARMA HOLDINGS CORP.
`Patent Owner
`
`IPR2015-01097 (US Patent No. 8,751,131)
`IPR2015-01099 (US Patent No. 8,669,290)
`IPR2015-01100 (US Patent No. 8,927,606)
`IPR2015-01105 (US Patent No. 8,871,813)1
`
`PETITIONER'S NOTICE OF CROSS-EXAMINATION OF
`SHIROU SAWA
`
`1 The word-for-word identical paper is filed in each proceeding identified in the
`heading. IPR2016-00089 has been joined with IPR2015-01097; IPR2016-00091
`has been joined with IPR2015-01100; and IPR2016-00090 has been joined with
`IPR2015-01105. Each of these joined proceedings includes Petitioners
`InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., Mylan
`Pharmaceuticals Inc., and Mylan Inc. (collectively, "InnoPharma") in additio
`$ (cid:9)
`the parties identified above.
`
`EXHIBIT
`1-(4?iro r6A;
`
`i3 la /co S1L
`
`ICI w
`
`
`
`Pursuant to 37 C.F.R. § 42.53, Lupin Ltd. and Lupin Pharmaceuticals Inc.
`
`(collectively, "Petitioners"), by and through its attorneys, will conduct a cross-
`
`examination by deposition of Shirou Sawa in connection with IPR2015-01097,
`
`IPR2015-01099, IPR2015-01100, and IPR2015-01105. Mr. Sawa's cross-
`
`examination will take place, as agreed by counsel for the parties, on March 18,
`
`2016, commencing at 9:00 a.m. (local time), at the offices of Finnegan, Henderson,
`
`Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC
`
`20001-4413. Counsel for Patent Owner has represented that Mr. Sawa is willing to
`
`appear at the time and location indicated above.
`
`The cross-examination will take place before a Notary Public or other officer
`
`authorized by law to administer oaths. It will be recorded using at least audiotape
`
`and/or stenographic means. Petitioners also intend to video record the cross-
`
`examination of Mr. Sawa. The arrangements for the reporter and videographer will
`
`be made by counsel for Petitioners. Counsel for Patent Owner has notified
`
`Petitioners that Mr. Sawa will require an interpreter, thus Petitioner will initiate a
`
`conference with the Board pursuant to 37 C.F.R. § 42.53(e) in due course.
`
`March 9, 2016
`
`Respectfully submitted,
`
`/Deborah Yellin/
`Deborah H. Yellin
`Reg. No. 45,904
`CROWELL & MORING LLP
`
`
`
`Intellectual Property Group
`P.O. Box 14300
`Washington, DC 20044-4300
`
`
`
`CERTIFICATION OF SERVICE
`
`The undersigned hereby certifies that the foregoing document entitled
`
`PETITIONER'S NOTICE OF CROSS-EXAMINATION OF SHIROU SAWA
`
`was served electronically via email on March 8, 2016 to Patent Owner's counsel of
`
`record and counsel of record for Petitioners InnoPharma at the following:
`
`Patent Owner
`
`Bryan.Diner@finnegan.com
`
`Justin.Hasford@finnegan.com
`
`Joshua.Goldberg@finnegan.com
`
`Petitioners InnoPharma
`
`Jitty.malik@alston.corn
`
`James.abe@alston.com
`
`Lance.soderstrom@alston.com
`
`March 9, 2016
`
`Respectfully submitted,
`
`/Deborah Yellin/
`Deborah H. Yellin
`Reg. No. 45,904
`CROWELL & MORING LLP
`Intellectual Property Group
`P.O. Box 14300
`Washington, DC 20044-4300